Critical appraisal:Ascierto PA, McArthur GA, Dréno B, Atkinson V, Liszkay G, Di Giacomo AM, et al 2016

From Cancer Guidelines Wiki

Critical Appraisal

Article being appraised

Ascierto PA, McArthur GA, Dréno B, Atkinson V, Liszkay G, Di Giacomo AM, et al. Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. Lancet Oncol 2016 Sep;17(9):1248-60 Available from: http://www.ncbi.nlm.nih.gov/pubmed/27480103.


Applicable clinical question

Key Facts

Study Design

randomised controlled trial

Number of Patients:

495

Total N=495 (intent to treat population) . Two treatemtn arms: 1) control arm: 248 placebo + vemurafenib; 2) 247 cobimetinib + vemurafenib
Reported outcome(s):

To compare the survival outcomes of previously untreated patients with histologically confirmed BRAFV600 mutant advanced melanoma that receive either Vemurafenib and placebo, or vemurafenib and cobimeitinib

Results of outcome(s):

Median PFS, months (95% CI) = Placebo and Vemurafenib: 7.2 (5.6-7.5); Cobimetinib and Vemurafenib: 12.3(9.5-13.4)

The median overall survival for patients treated with cobimetinib and vemurafenib was 22·3 months (95% CI 20·3–not estimable) compared with 17·4 months (95% CI 15·0–19·8) for patients treated with vemurafenib (HR 0·70 [95% CI 0·55–0·90], p=0·005; fi gure 4A). 1-year overall survival was 74·5% (95% CI 68·9–80·2) in the cobimetinib and vemurafenib group and 63·8% (57·6–70·0) in the vemurafenib group; 2-year overall survival was 48·3% (41·4–55·2) and 38·0% (31·3–44·7), respectively.

Includes an economic evaluation

no

Evidence ratings

Level of evidence

II

Risk of bias
High risk of bias Comments: Please replace this text and include any additional comments in regards to your risk of bias rating

Risk of bias assessment: randomised controlled trial

Was the trial double-blinded?
I am reasonably certain that the trial was double-blinded (eg identical placebo, active placebo, double-dummy, no revealing side-effects).
Was the treatment allocation schedule concealed?
No concealment or unclear (e.g. no approach described, open randomisation lists, person doing recruitment tossing a coin).
Were all randomised participants included in the analysis?
No exclusions or survival analysis used with all subjects included (>95% follow-up for all groups).
The field below is not considered when calculating the risk of bias rating
How was the allocation schedule generated?
Adequate (e.g. random number table, computer random generator, coin tossing, card shuffling)
Result of appraisal

Jutta's tick icon.png Included




Completed by

Meghna Kakani


Jutta's tick icon.png This appraisal has been completed.


Article
Ascierto PA, McArthur GA, Dréno B, Atkinson V, Liszkay G, Di Giacomo AM, et al. Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. Lancet Oncol 2016 Sep;17(9):1248-60 Available from: http://www.ncbi.nlm.nih.gov/pubmed/27480103.
Assigned to
User:Meghna.kakani
Topic area
Guidelines:Melanoma
Clinical question
Form
Form:Critical appraisal


Section below only relevant for Cancer Council Project Officer

Edit appraisal assignment